Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Shanghai Pharmaceuticals Holding Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥10.70 |
52 Week High | CN¥16.60 |
52 Week Low | CN¥10.18 |
Beta | 0.24 |
1 Month Change | -10.08% |
3 Month Change | -1.29% |
1 Year Change | -31.59% |
3 Year Change | -36.39% |
5 Year Change | -35.07% |
Change since IPO | -43.27% |
Recent News & Updates
Recent updates
Shareholder Returns
2607 | HK Healthcare | HK Market | |
---|---|---|---|
7D | -3.3% | -0.5% | -2.8% |
1Y | -31.6% | -33.9% | -15.0% |
Return vs Industry: 2607 exceeded the Hong Kong Healthcare industry which returned -34.9% over the past year.
Return vs Market: 2607 underperformed the Hong Kong Market which returned -16.4% over the past year.
Price Volatility
2607 volatility | |
---|---|
2607 Average Weekly Movement | 5.7% |
Healthcare Industry Average Movement | 6.6% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.8% |
10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 2607 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2607's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 48,164 | Bo Shen | www.sphchina.com |
Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, systemic anti-infection, mental nerve, anti-tumor, oncology, respiratory system, nervous system, auto-immunity, hypertension, neuromyelitis, diabetes, anticholinesterase, polypeptide hormones uterine tonic, antihistamine, anti-inflammatory, anesthetic, immunomodulatory, antiviral, reflux esophagitis, analgesics, weight management, malignant peritoneal effusion, ulcerative colitis, myasthenia gravis, burn injury, anticoagulant, anti-epileptic, anticonvulsant, Alzheimer’s, and inflammatory bowel diseases.
Shanghai Pharmaceuticals Holding Co., Ltd Fundamentals Summary
2607 fundamental statistics | |
---|---|
Market cap | HK$62.76b |
Earnings (TTM) | HK$4.08b |
Revenue (TTM) | HK$281.63b |
17.3x
P/E Ratio0.2x
P/S RatioIs 2607 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2607 income statement (TTM) | |
---|---|
Revenue | CN¥260.30b |
Cost of Revenue | CN¥229.37b |
Gross Profit | CN¥30.93b |
Other Expenses | CN¥27.16b |
Earnings | CN¥3.77b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
Earnings per share (EPS) | 1.02 |
Gross Margin | 11.88% |
Net Profit Margin | 1.45% |
Debt/Equity Ratio | 62.0% |
How did 2607 perform over the long term?
See historical performance and comparison